Gene

Venetoclax

Biology

Decitabine

Cancer research

Biochemistry

DNA methylation

Leukemia

Environmental health

Placebo

Alternative medicine

Myeloid leukemia

Genetics

Myeloid

Regimen

Population

Internal medicine

Oncology

Medicine

Chemistry

Gastroenterology

Hypomethylating agent

Chronic lymphocytic leukemia

Gene expression

Pathology

Azacitidine

New England Journal of Medicine

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia